Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook
Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.
Share
Why It Matters
Natera did more genetic tests than ever before, and people want their cancer tests especially. The company feels confident enough to promise even better results ahead, which often means the business is working well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.